Published in J Lipid Res on March 15, 2013
Antioxidants, inflammation and cardiovascular disease. World J Cardiol (2014) 1.20
Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial. Acta Diabetol (2015) 0.83
Pharmacogenomic interaction between the Haptoglobin genotype and vitamin E on atherosclerotic plaque progression and stability. Atherosclerosis (2015) 0.78
Vitamin E: the enigmatic one! J Lipid Res (2013) 0.78
Dietary Antioxidants as Modifiers of Physiologic Adaptations to Exercise. Med Sci Sports Exerc (2015) 0.78
Side-effects of domestication: cultivated legume seeds contain similar tocopherols and fatty acids but less carotenoids than their wild counterparts. BMC Plant Biol (2014) 0.78
Evidence for beneficial effects of vitamin E. Korean J Intern Med (2015) 0.77
The Cardioprotective Effect of Vitamin E (Alpha-Tocopherol) Is Strongly Related to Age and Gender in Mice. PLoS One (2015) 0.75
Role of Haptoglobin in Health and Disease: A Focus on Diabetes. Clin Diabetes (2016) 0.75
α-Tocopherol supplementation reduces 5-nitro-γ-tocopherol accumulation by decreasing γ-tocopherol in young adult smokers. Free Radic Res (2015) 0.75
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. JAMA (2008) 8.32
MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 7.41
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35
Identification of the haemoglobin scavenger receptor. Nature (2001) 7.05
Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) Lancet (1996) 6.48
Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet (2001) 6.38
Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med (1993) 6.37
Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet (2000) 6.19
Vitamin E consumption and the risk of coronary disease in women. N Engl J Med (1993) 5.39
Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 5.09
Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem (1996) 4.02
Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care (2003) 3.68
Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol (2005) 3.02
Haptoglobin: the evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet (1982) 2.42
Structure-function analysis of the antioxidant properties of haptoglobin. Blood (2001) 2.17
Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Cardiol (2002) 2.08
Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis: the Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation (2002) 1.99
Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol (2007) 1.96
Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res (2005) 1.71
Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes (2008) 1.62
New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol (2004) 1.59
Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes (2005) 1.53
Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care (2003) 1.43
Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation (2002) 1.43
Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics (2010) 1.42
Inhibition of cell proliferation by alpha-tocopherol. Role of protein kinase C. J Biol Chem (1991) 1.41
Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care (2002) 1.40
Vitamin E and its function in membranes. Prog Lipid Res (1999) 1.29
Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med (1998) 1.21
The effects of alpha tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin 1 beta secretion, and monocyte adhesion to endothelium. J Clin Invest (1996) 1.19
Potential antiatherogenic mechanisms of ascorbate (vitamin C) and alpha-tocopherol (vitamin E). Circ Res (2000) 1.19
Haptoglobin phenotypes differ in their ability to inhibit heme transfer from hemoglobin to LDL. Biochemistry (2004) 1.19
The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care (2004) 1.18
Current Concepts of the Role of Oxidized LDL Receptors in Atherosclerosis. Curr Atheroscler Rep (2012) 1.16
Vitamin E: the shrew waiting to be tamed. Free Radic Biol Med (2008) 1.09
The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Atherosclerosis (2010) 1.08
d-alpha-tocopherol inhibition of vascular smooth muscle cell proliferation occurs at physiological concentrations, correlates with protein kinase C inhibition, and is independent of its antioxidant properties. Proc Natl Acad Sci U S A (1995) 1.07
Modulation of signal transduction by vitamin E. Mol Aspects Med (2007) 1.06
Alpha-tocopherol decreases interleukin-1 beta release from activated human monocytes by inhibition of 5-lipoxygenase. Arterioscler Thromb Vasc Biol (1999) 1.05
alpha-tocopherol inhibits the respiratory burst in human monocytes. Attenuation of p47(phox) membrane translocation and phosphorylation. J Biol Chem (1998) 1.03
Inhibition of THP-1 cell adhesion to endothelial cells by alpha-tocopherol and alpha-tocotrienol is dependent on intracellular concentration of the antioxidants. Free Radic Biol Med (2003) 0.99
Alpha-tocopherol inhibits agonist-induced monocytic cell adhesion to cultured human endothelial cells. J Clin Invest (1994) 0.98
Anti-atherosclerotic effects of vitamin E--myth or reality? J Cell Mol Med (2004) 0.98
The effect of vitamin therapy on the progression of coronary artery atherosclerosis varies by haptoglobin type in postmenopausal women. Diabetes Care (2004) 0.98
Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int (2004) 0.98
Protein phosphatase 2A and protein kinase Calpha are physically associated and are involved in Pseudomonas aeruginosa-induced interleukin 6 production by mast cells. J Biol Chem (2001) 0.96
Modulation by alpha- and gamma-tocopherol and oxidized low-density lipoprotein of apoptotic signaling in human coronary smooth muscle cells. Biochem Pharmacol (2000) 0.93
Effect of vitamin E on human aortic endothelial cell production of chemokines and adhesion to monocytes. Atherosclerosis (1999) 0.93
Alpha-tocopherol decreases tumor necrosis factor-alpha mRNA and protein from activated human monocytes by inhibition of 5-lipoxygenase. Free Radic Biol Med (2005) 0.92
Vitamin E supplementation suppresses macrophage accumulation and endothelial cell expression of adhesion molecules in the aorta of hypercholesterolemic rabbits. Atherosclerosis (2004) 0.92
Divergent effects of alpha-tocopherol and vitamin C on the generation of dysfunctional HDL associated with diabetes and the Hp 2-2 genotype. Antioxid Redox Signal (2010) 0.89
Cardiovascular disease in diabetes: where does glucose fit in? J Clin Endocrinol Metab (2011) 0.89
Clinical practice and implications of recent diabetes trials. Curr Opin Cardiol (2011) 0.88
Antagonistic effects of oxidized low density lipoprotein and alpha-tocopherol on CD36 scavenger receptor expression in monocytes: involvement of protein kinase B and peroxisome proliferator-activated receptor-gamma. J Biol Chem (2006) 0.88
alpha-Tocopherol protects against expression of adhesion molecules on neutrophils and endothelial cells. Biofactors (1998) 0.87
Vitamin E inhibits protein kinase C activity. Biochem Biophys Res Commun (1988) 0.87
Vitamin E protects against polymorphonuclear leukocyte-dependent adhesion to endothelial cells. J Leukoc Biol (1999) 0.87
Haptoglobin phenotype as a predictive factor of mortality in diabetic haemodialysis patients. Ann Clin Biochem (2004) 0.86
Vitamin E inhibits lipid peroxidation-induced adhesion molecule expression in endothelial cells and decreases soluble cell adhesion molecules in healthy subjects. Cardiovasc Res (2003) 0.85
Antioxidant vitamins--benefits not yet proved. N Engl J Med (1994) 0.83
Vitamin E supplementation reduces plasma vascular cell adhesion molecule-1 and von Willebrand factor levels and increases nitric oxide concentrations in hypercholesterolemic patients. J Clin Endocrinol Metab (2002) 0.83
Pharmacogenomic application of the haptoglobin genotype in the prevention of diabetic cardiovascular disease. Pharmacogenomics (2008) 0.82
Effect of vitamin E on prostacyclin (PGI2) and prostaglandin (PG) E2 production by human aorta endothelial cells: mechanism of action. Ann N Y Acad Sci (2004) 0.81
Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA). J Am Coll Nutr (1992) 0.81
Antioxidant vitamins and cardiovascular disease. Nutr Rev (1997) 0.81
Vitamin E supplementation and the risk of heart failure in women. Circ Heart Fail (2012) 0.81
Alpha-Tocopherol and endothelial nitric oxide synthesis. Ann N Y Acad Sci (2004) 0.79
Prolonged, low dose alpha-tocopherol therapy counteracts intercellular cell adhesion molecule-1 activation. Clin Chim Acta (2002) 0.77
Alpha-tocopherol amplifies phosphorylation of endothelial nitric oxide synthase at serine 1177 and its short-chain derivative trolox stabilizes tetrahydrobiopterin. Free Radic Biol Med (2004) 0.77
Inhibitory effect of vitamin E on proinflammatory cytokines-and endotoxin-induced nitric oxide release in alveolar macrophages. Life Sci (2005) 0.77
Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E. Expert Rev Cardiovasc Ther (2007) 0.77
Neovascularization in human atherosclerosis. Circulation (2006) 2.44
Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res (2003) 1.99
Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol (2007) 1.96
Haptoglobin: basic and clinical aspects. Antioxid Redox Signal (2010) 1.94
Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem (2002) 1.90
Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J Am Coll Cardiol (2013) 1.85
Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res (2005) 1.71
Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype. Diabetes (2008) 1.64
Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes (2005) 1.53
ELISA for determination of the haptoglobin phenotype. Clin Chem (2004) 1.44
Haptoglobin genotype is predictive of major adverse cardiac events in the 1-year period after percutaneous transluminal coronary angioplasty in individuals with diabetes. Diabetes Care (2003) 1.43
Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics (2010) 1.42
Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol (2006) 1.38
Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res (2007) 1.37
Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ Res (2006) 1.32
Haptoglobin genotype modulates the balance of Th1/Th2 cytokines produced by macrophages exposed to free hemoglobin. Atherosclerosis (2006) 1.26
In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc Health Risk Manag (2005) 1.22
The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care (2004) 1.18
Haptoglobin phenotype and coronary artery collaterals in diabetic patients. Atherosclerosis (2002) 1.13
A 40-bp RNA element that mediates stabilization of vascular endothelial growth factor mRNA by HuR. J Biol Chem (2002) 1.10
Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J Agric Food Chem (2008) 1.09
The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Atherosclerosis (2010) 1.08
Haptoglobin 2-2 genotype determines chronic vasospasm after experimental subarachnoid hemorrhage. Stroke (2007) 1.07
Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. J Am Coll Cardiol (2008) 1.03
Increased blood vessel density provides the mole rat physiological tolerance to its hypoxic subterranean habitat. FASEB J (2005) 1.02
Increased expression of oxidation-specific epitopes and apoptosis are associated with haptoglobin genotype: possible implications for plaque progression in human atherosclerosis. J Am Coll Cardiol (2012) 0.99
Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype. Atherosclerosis (2011) 0.97
Haptoglobin genotype predicts development of coronary artery calcification in a prospective cohort of patients with type 1 diabetes. Cardiovasc Diabetol (2011) 0.96
Haptoglobin genotype and cardiovascular outcomes in diabetes mellitus - natural history of the disease and the effect of vitamin E treatment. Meta-analysis of the medical literature. Eur J Intern Med (2012) 0.95
Haptoglobin genotype and its role in diabetic cardiovascular disease. J Cardiovasc Transl Res (2012) 0.94
New horizons for VEGF. Is there a role for nuclear localization? Acta Histochem (2005) 0.93
Controlled delivery of nitric oxide inhibits leukocyte migration and prevents vasospasm in haptoglobin 2-2 mice after subarachnoid hemorrhage. Neurosurgery (2009) 0.93
HDL dysfunction in diabetes: causes and possible treatments. Expert Rev Cardiovasc Ther (2012) 0.92
Hypothesis--haptoglobin genotype and diabetic nephropathy. Nat Clin Pract Nephrol (2007) 0.92
Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus. Am J Physiol Renal Physiol (2009) 0.91
Haptoglobin genotype determines myocardial infarct size in diabetic mice. J Am Coll Cardiol (2006) 0.90
Haptoglobin phenotype in women with preeclampsia. Endocrine (2010) 0.90
Divergent effects of alpha-tocopherol and vitamin C on the generation of dysfunctional HDL associated with diabetes and the Hp 2-2 genotype. Antioxid Redox Signal (2010) 0.89
Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype. Arterioscler Thromb Vasc Biol (2008) 0.89
Haptoglobin genotype and its role in determining heme-iron mediated vascular disease. Pharmacol Res (2012) 0.89
Haptoglobin genotype and the rate of renal function decline in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes (2013) 0.88
Antioxidant vitamins and their use in preventing cardiovascular disease. Molecules (2010) 0.87
The haptoglobin 2-2 genotype is associated with increased redox active hemoglobin derived iron in the atherosclerotic plaque. Atherosclerosis (2009) 0.87
Haptoglobin phenotype as a predictive factor of mortality in diabetic haemodialysis patients. Ann Clin Biochem (2004) 0.86
An enzyme linked immunosorbent assay (ELISA) for the determination of the human haptoglobin phenotype. Clin Chem Lab Med (2013) 0.85
Restoration of blood flow by using continuous perimuscular infiltration of plasmid DNA encoding subterranean mole rat Spalax ehrenbergi VEGF. Proc Natl Acad Sci U S A (2003) 0.85
The genetics of vascular complications in diabetes mellitus. Cardiol Clin (2010) 0.85
Haptoglobin genotype is a determinant of survival and cardiac remodeling after myocardial infarction in diabetic mice. Cardiovasc Diabetol (2009) 0.84
Vascular endothelial growth factor (VEGF) fails to improve blood flow and to promote collateralization in a diabetic mouse ischemic hindlimb model. Cardiovasc Diabetol (2003) 0.84
Haptoglobin type and 30-day mortality in diabetic individuals presenting with acute myocardial infarction. Diabetes Care (2003) 0.83
Pharmacogenomic application of the haptoglobin genotype in the prevention of diabetic cardiovascular disease. Pharmacogenomics (2008) 0.82
Currently available versions of genome-wide association studies cannot be used to query the common haptoglobin copy number variant. J Am Coll Cardiol (2013) 0.82
Tyrosine kinases inhibitors block Fas-mediated deleterious effects in normoxic and hypoxic ventricular myocytes. J Mol Cell Cardiol (2003) 0.82
Retinal capillary basement membrane thickness in diabetic mice genetically modified at the haptoglobin locus. Diabetes Metab Res Rev (2007) 0.81
Poor lysosomal membrane integrity in proximal tubule cells of haptoglobin 2-2 genotype mice with diabetes mellitus. Free Radic Biol Med (2012) 0.80
Increased renal hypertrophy in diabetic mice genetically modified at the haptoglobin locus. Diabetes Metab Res Rev (2005) 0.80
Haptoglobin 1-1 genotype and the risk of life-threatening Streptococcus infection: evolutionary implications. J Infect (2006) 0.79
Haptoglobin phenotypes, which one is better and when? Clin Lab (2006) 0.79
Role of haptoglobin phenotype in end-stage kidney disease. Nephron Exp Nephrol (2004) 0.79
Serum chelatable redox-active iron is an independent predictor of mortality after myocardial infarction in individuals with diabetes. Diabetes Care (2004) 0.79
Haptoglobin genotype and endothelial function in diabetes mellitus: a pilot study. Eur J Appl Physiol (2009) 0.79
Regulation of CD163 associated casein kinase II activity is haptoglobin genotype dependent. Mol Cell Biochem (2008) 0.78
Haptoglobin polymorphism is a risk factor for cardiovascular disease in patients with obstructive sleep apnea syndrome. Sleep (2003) 0.78
Patient selection and vitamin E treatment in diabetes mellitus. Expert Rev Cardiovasc Ther (2013) 0.78
Haptoglobin: A major susceptibility gene for diabetic vascular complications. Exp Clin Cardiol (2002) 0.78
Haptoglobin phenotype and the risk of restenosis after coronary artery stent implantation. Am J Cardiol (2002) 0.77
Is it time to screen for the haptoglobin genotype to assess the cardiovascular risk profile and vitamin E therapy responsiveness in patients with diabetes? Curr Diab Rep (2012) 0.77
Vitamin E and diabetic nephropathy in mice model and humans. World J Nephrol (2013) 0.77
Is the Hp 2-2 diabetic mouse model a good model to study diabetic nephropathy? Diabetes Res Clin Pract (2013) 0.76
Antioxidants in the prevention of atherosclerosis: the importance of proper patient selection. Clin Nutr (2009) 0.76
The association of Haptoglobin polymorphism with Crohn's disease in Israel. J Crohns Colitis (2008) 0.76
Haptoglobin genotype and the iron hypothesis of atherosclerosis. Atherosclerosis (2011) 0.76
Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction. Pharmgenomics Pers Med (2009) 0.75
Genetics of redox systems and their relationship with cardiovascular disease. Curr Atheroscler Rep (2011) 0.75
Cholesterol efflux capacity and atherosclerosis. N Engl J Med (2011) 0.75
Haptoglobin phenotypes and in vitro fertilization treatment outcomes. Syst Biol Reprod Med (2013) 0.75
Angiogenesis--an update. Pediatr Endocrinol Rev (2005) 0.75
Haptoglobin phenotype in age-related macular degeneration patients. Am J Ophthalmol (2003) 0.75
Haptoglobin 2-2 Genotype Is Associated With Cerebral Salt Wasting Syndrome in Aneurysmal Subarachnoid Hemorrhage. Neurosurgery (2016) 0.75
Haptoglobin Genotype as a Determinant of Benefit or Harm From Niacin for Participants With Diabetes. J Am Coll Cardiol (2016) 0.75
Changing the face of diabetic care with haptoglobin genotype selection and vitamin e. Rambam Maimonides Med J (2011) 0.75